Press Releases
Recipharm and Astimex Pharma form new development and manufacturing collaboration
Recipharm AB and Astimex Pharma AB have today announced the formation of a collaboration agreement for the development and manufacture of a pharmaceutical product. The formulation development work will take place at the Recipharm...
Press Releases
Cytheris publication in Blood demonstrates CYT107 reverses lymphopenia and increases virus-specific immunity post stem cell transplantation
Cytheris SA, a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today the publication of a paper demonstrating that Cytheris' CYT107, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7) can enhance immune T cell recovery after...
Press Releases
GenoLogics Unveils Clarity LIMS for CLIA-Certified Next Generation Sequencing Labs
Bio-IT World Europe Conference – GenoLogics Life Sciences Software, a leading provider of laboratory information management systems (LIMS) designed for today’s omics labs, unveiled Clarity LIMS, a revolutionary LIMS that sets the bar for LIMS in clinical and...
Press Releases
Affimed Therapeutics AG: Affimed Raises Eur 15.5 Million in a Series D Financing Round
Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of EUR 15.5 million. The proceeds from this transaction will be used to fund the clinical...
Press Releases
Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD
Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD(recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS)....
Press Releases
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets. Under the terms of the revised agreement,...
Press Releases
CiToxLAB Group announces a 34 per cent revenue increase for the first half of 2012
CiToxLAB Group, a leading CRO in the field of non-clinical research, announces today that the group’s consolidated first half 2012 revenues reached EUR 37.2M (USD 48.4 million approximately). This marks a 34 per cent increase compared with the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read